Airfinity Biorisk
Biorisks are a real threat to humanity, national security, and business operations. Airfinity is a first-of-its-kind disease forecasting company. It tracks, simulates, and predicts population level disease outcomes in real-time to inform decisions that reduces and mitigates that risk.
Airfinity's biorisk solution equips decision makers with a holistic overview of the global infectious disease risk situation, providing assessment and predictions for 160+ viral, bacterial and fungal pathogens to prevent the spread and subsequent impact of future outbreaks.
A proprietary outbreak risk index is assigned to each new outbreak, based on 15+ metrics across country and disease level data points. Through expert analysis and assessment, we provide actionable insight into disease dynamics and forecasted disease burden in affected areas.
Access risk assessments and intelligence tailored to your geographical footprint, using vast amounts of data signals to quickly track, predict and assess ongoing and incoming biological risks to your locations.
Get in touch for more information
Fill out the short form to request more information and a member of the team will be in touch.
Get in touch for more information
Fill out the short form to request more information and a member of the team will be in touch.
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”
Iskra Reic, Executive Vice-President
Astrazeneca
“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”
Sir John Bell ,
University of Oxford